Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 124.55B |
| Revenue (ttm) | 53.69B |
| Net Income (ttm) | 8.41B |
| Shares Out | n/a |
| EPS (ttm) | 1.48 |
| PE Ratio | 14.82 |
| Forward PE | 8.72 |
| Dividend | 1.53 (7.01%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 3,756 |
| Average Volume | 13,499 |
| Open | 21.80 |
| Previous Close | 21.69 |
| Day's Range | 21.78 - 21.91 |
| 52-Week Range | 18.77 - 26.40 |
| Beta | n/a |
| RSI | 53.20 |
| Earnings Date | Feb 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Healthy Returns: What to expect from pharma at the JPM conference
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
It could be another tough year for the once-soaring drugmaker.
Pfizer inks licensing deal with Madrigal for MASH candidate
UPRO, SPGI, DHR, PFE: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P 500 (Symbol: UPRO) where we have detected an ap...
Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks
Some safe dividend stocks also offer high yields. Their payouts are high but aren't risky, and are backed by strong fundamentals.
Pfizer Turns To AI Where Drug Risk Is Highest
Pfizer Turns To AI Where Drug Risk Is Highest
Pfizer Partners with Boltz to Use AI in Drug Discovery
Pfizer Partners with Boltz to Use AI in Drug Discovery
Pfizer (PFE) Partners with Boltz for AI-Driven Drug Discovery
Pfizer (PFE) Partners with Boltz for AI-Driven Drug Discovery
Pfizer collaborating with Boltz to use AI models for drug discovery
Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity
SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity.
Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?
This big pharma stock still faces significant challenges in the new year.
3 Drug Stocks to Buy at a Discount
Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which ...
This Could Be Key to Pfizer's Turnaround in 2026
Key PointsPfizer has been making deals in recent years to enhance its long-term growth potential.
This Could Be Key to Pfizer's Turnaround in 2026
Pfizer has been making deals in recent years to enhance its long-term growth potential. Last month, it reached a GLP-1 licensing deal with a China-based drug company.
UBS Assumes Neutral Rating for Pfizer (PFE) with $25 Price Target | PFE Stock News
UBS Assumes Neutral Rating for Pfizer (PFE) with $25 Price Target | PFE Stock News
Quant Q&A With Steven Cress
Steven Cress answers your questions! Credo Technology maintains A+ momentum rating, outperforming its sector across multiple timeframes despite recent stagnation concerns.
Pfizer: 2026 Guidance Points To Continued Margin And Growth Pressure
America's new vaccine doctrine for children replaces data with dogma
In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being sol...
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced a strategic...
5 of the Safest Ultra-High-Yield Dividend Stocks You Can Confidently Buy for 2026
Dividend stocks have more than doubled the average annual return of non-payers spanning more than half a century. Though ultra-high-yield stocks -- those with yields four or more times greater than th...
This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping)
The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the developmental work this pharma icon has going on.
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morga...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at...
Better Dividend Stock: Ford vs. Pfizer
Both Ford and Pfizer have very attractive dividend yields.